<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ojrdrt</journal-id><journal-title-group><journal-title xml:lang="ru">Онкологический журнал: лучевая диагностика, лучевая терапия</journal-title><trans-title-group xml:lang="en"><trans-title>Journal of oncology: diagnostic radiology and radiotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7593</issn><issn pub-type="epub">2713-167X</issn><publisher><publisher-name>НЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37174/2587-7593-2026-9-1-9-15</article-id><article-id custom-type="elpub" pub-id-type="custom">ojrdrt-507</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЛУЧЕВАЯ ТЕРАПИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>RADIOTHERAPY</subject></subj-group></article-categories><title-group><article-title>Сравнительный анализ онкологической эффективности и косметических результатов ускоренного частичного облучения больных раком молочной железы с помощью высокодозной брахитерапии и дистанционной лучевой терапии</article-title><trans-title-group xml:lang="en"><trans-title>Comparative Analysis of Oncological Efficacy and Cosmetic Outcomes of Accelerated Partial Breast Irradiation Techniques: Multicatheter Interstitial Brachytherapy and Conformal External Beam Radiotherapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9189-6417</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Брянцева</surname><given-names>Ж. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bryantseva</surname><given-names>Zh. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Санкт-Петербург, пос. Песочный, ул. Ленинградская, д. 68, 197758</p></bio><bio xml:lang="en"><p>Saint Petersburg, Pesochny, 68 Leningradskaya St., 197758</p></bio><email xlink:type="simple">zhanna-dr@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7185-1967</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новиков</surname><given-names>С. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikov</surname><given-names>S. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Санкт-Петербург, пос. Песочный, ул. Ленинградская, д. 68, 197758</p></bio><bio xml:lang="en"><p>Saint Petersburg, Pesochny, 68 Leningradskaya St., 197758</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0018-7197</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Акулова</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Akulova</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Санкт-Петербург, пос. Песочный, ул. Ленинградская, д. 68, 197758</p></bio><bio xml:lang="en"><p>Saint Petersburg, Pesochny, 68 Leningradskaya St., 197758</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4898-9159</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Криворотько</surname><given-names>П. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Krivorotko</surname><given-names>P. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Санкт-Петербург, пос. Песочный, ул. Ленинградская, д. 68, 197758</p></bio><bio xml:lang="en"><p>Saint Petersburg, Pesochny, 68 Leningradskaya St., 197758</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1471-9473</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Табагуа</surname><given-names>Т. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Tabagua</surname><given-names>T. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Санкт-Петербург, пос. Песочный, ул. Ленинградская, д. 68, 197758</p></bio><bio xml:lang="en"><p>Saint Petersburg, Pesochny, 68 Leningradskaya St., 197758</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6864-6348</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Крживицкий</surname><given-names>П. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Krzhivitskiy</surname><given-names>P. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Санкт-Петербург, пос. Песочный, ул. Ленинградская, д. 68, 197758</p></bio><bio xml:lang="en"><p>Saint Petersburg, Pesochny, 68 Leningradskaya St., 197758</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9732-7920</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хорошавина</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Khoroshavina</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Санкт-Петербург, пос. Песочный, ул. Ленинградская, д. 68, 197758</p></bio><bio xml:lang="en"><p>Saint Petersburg, Pesochny, 68 Leningradskaya St., 197758</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3130-3624</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попова</surname><given-names>Н. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Popova</surname><given-names>N. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Санкт-Петербург, пос. Песочный, ул. Ленинградская, д. 68, 197758</p></bio><bio xml:lang="en"><p>Saint Petersburg, Pesochny, 68 Leningradskaya St., 197758</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр онкологии им. Н. Н. Петрова Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.N. Petrov National Medicine Research Center of Oncology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>28</day><month>03</month><year>2026</year></pub-date><volume>9</volume><issue>1</issue><fpage>9</fpage><lpage>15</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Брянцева Ж.В., Новиков С.Н., Акулова И.А., Криворотько П.В., Табагуа Т.Т., Крживицкий П.И., Хорошавина А.А., Попова Н.С., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Брянцева Ж.В., Новиков С.Н., Акулова И.А., Криворотько П.В., Табагуа Т.Т., Крживицкий П.И., Хорошавина А.А., Попова Н.С.</copyright-holder><copyright-holder xml:lang="en">Bryantseva Z.V., Novikov S.N., Akulova I.A., Krivorotko P.V., Tabagua T.T., Krzhivitskiy P.I., Khoroshavina A.A., Popova N.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.oncoradjournal.ru/jour/article/view/507">https://www.oncoradjournal.ru/jour/article/view/507</self-uri><abstract><p>Введение: Ускоренное парциальное облучение молочной железы (УПОМЖ) является стандартом лучевого лечения больных ранним раком молочной железы (РМЖ). При проведении УПОМЖ применяются различные методы подведения дозы, но наиболее часто используется конформная дистанционная лучевая терапия (ДЛТ) или внутритканевая брахитерапия источником 192Ir высокой мощности дозы (ВДБТ). Цель исследования: Сравнить показатели онкологической эффективности (выживаемость без рецидива в ипсилатеральной молочной железе (БРВ-ИМЖ) и безрецидивной выживаемости (БРВ)) и косметические результаты у больных РМЖ после органосохраняющих операций и послеоперационной УПОМЖ методом ВДБТ или ДЛТ. Материалы и методы: В период с 2016 по 2022 гг. у 183 больных РМЖ рТ1-2N0M0 после органосохраняющей операции проводилось УПОМЖ на область ложа удаленной опухоли. В группе УПОМЖ-ДЛТ (n = 85) облучение проводилось в режиме 10 фракций по 3,85 Гр (суммарная эквивалентная доза (СЭД) — 52 Гр (α/β = 3)). В группе УПОМЖ-ВДБТ (n = 98) — 8 фракций по 4 Гр в течение 4 дней, 2 фракции в день с интервалом более 6 часов (СЭД 50 Гр (α/β = 3)). Все пациентки соответствовали критериям GEC-ESTRO для проведения УПОМЖ. Для оценки косметических результатов через 3 и 5 лет наблюдения проведен стандартизированный телефонный опрос с использованием шести вопросов опросника BREAST-Q. Ответы суммировались в баллы (от 6 до 18) и распределялись по категориям: «отличный», «хороший», «удовлетворительный» и «неудовлетворительный» результат. Результаты: Медиана наблюдения составила 45 месяцев в группе УПОМЖ-ДЛТ и 70 месяцев в группе УПОМЖ-ВДБТ. Трехлетняя БРВ-ИМЖ была равна 100 % в обеих группах. Трехлетняя БРВ составила 97,6 % в группе УПОМЖ-ДЛТ и 98,0 % УПОМЖ-ВДБТ (р = 1,0). В группе УПОМЖ-ВДБТ пятилетние БРВ-ИМЖ достигла 95,1 % и БРВ — 93,9 %. Оценка косметических результатов через 3 года показала, что в группе УПОМЖ-ДЛТ «отличный» результат зафиксирован у 49 из 54 пациенток (90,7 %), в то время как в группе ВДБТ все 53 опрошенные пациентки (100 %) оценили результат как «отличный» (p = 0,059). Через 5 лет «отличный» результат в группе УПОМЖ-ВДБТ сохранился у всех пациенток. Выводы: Оба метода УПОМЖ (ВДБТ и ДЛТ) демонстрируют сопоставимую высокую эффективность в отношении локального контроля на трехлетнем сроке наблюдения. При этом УПОМЖ методом ВДБТ демонстрирует тенденцию к более благоприятным долгосрочным косметическим результатам в сравнении с УПОМЖ-ДЛТ.</p></abstract><trans-abstract xml:lang="en"><p>Accelerated partial breast irradiation (APBI) is a standard radiotherapy approach for patients with early-stage breast cancer. Various techniques can be employed to deliver APBI, with external beam radiotherapy (EBRT) and interstitial high-dose-rate brachytherapy (HDR-BT) using an Ir-192 source being the most commonly used in clinical practice. Purpose: To compare the oncological efficacy and cosmetic outcomes in breast cancer patients treated with postoperative APBI using either HDR-BT or EBRT. The primary efficacy endpoints were ipsilateral breast tumor recurrence-free survival (IBTR-FS) and recurrence-free survival (RFS). Materials and Methods: Between 2016 and 2022, 183 patients with рТ1-2N0M0 breast cancer underwent APBI to the tumor bed after breast-conserving surgery. In the APBI-EBRT group (n = 85), irradiation was delivered in 10 fractions of 3.85 Gy (total equivalent dose   (α/β = 3) — 52 Gy). In the APBI-HDR-BT group (n = 98), we delivered 8 fractions of 4 Gy over 4 days (two fractions per day with &gt;6-hour   intervals, total equivalent dose (α/β = 3) — 50 Gy). All patients met the GEC-ESTRO criteria for APBI. Cosmetic outcomes were assessed at 3 and 5 years post-treatment via a standardized telephone interview using six items from the BREAST-Q questionnaire. Responses were summed into a score (range: 6–18) and categorized as ‘excellent’, ‘good’, ‘satisfactory’, or ‘unsatisfactory’. Results: The median follow-up was 45 months in the APBI-EBRT group and 70 months in the APBI-HDR-BT group. The 3-year IBTR-FS was 100 % in both groups. The 3-year RFS was 97.6 % in the APBI-EBRT group and 98.0 % in the APBI-HDR-BT group (p = 1.0). In the   APBI-HDR-BT group, the 5-year IBTR-FS and RFS rates were 95.1 % and 93.9 %, respectively.   The 3-year cosmetic assessment revealed an ‘excellent’ result in 49 of 54 patients (90.7 %) in the APBI-EBRT group, while all 53 patients (100 %) in the APBI-HDR-BT group reported an ‘excellent’ result (p = 0.059). At the 5-year assessment, an ‘excellent’ cosmetic outcome was maintained in all patients in the APBI-HDR-BT group. Conclusion: Both APBI techniques (HDR-BT and EBRT) demonstrated comparably high efficacy in terms of local control after 3-year of follow-up. However, APBI delivered with HDR-BT showed a trend towards more favorable long-term cosmetic outcomes compared to APBI delivered with EBRT.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>брахитерапия</kwd><kwd>парциальная лучевая терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>brachytherapy</kwd><kwd>accelerated partial breast irradiation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Strnad V, Polgár C, Ott OJ, et al. Accelerated partial breast irradiation us ing sole interstitial multicatheter brachytherapy compared with whole breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial. Lancet Oncol. 2023;24(3):262-72. https://doi.org/10.1016/S1470-2045(23)00018-9</mixed-citation><mixed-citation xml:lang="en">Strnad V, Polgár C, Ott OJ, et al. Accelerated partial breast irradiation us ing sole interstitial multicatheter brachytherapy compared with whole breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial. Lancet Oncol. 2023;24(3):262-72. https://doi.org/10.1016/S1470-2045(23)00018-9</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Meduri B, Baldissera A, Iotti C, et al. Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial. J Clin Oncol. 2023;41(12):2201-10. https://doi.org/10.1200/JCO.22.01485</mixed-citation><mixed-citation xml:lang="en">Meduri B, Baldissera A, Iotti C, et al. Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial. J Clin Oncol. 2023;41(12):2201-10. https://doi.org/10.1200/JCO.22.01485</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390(10099):1048-60. https://doi.org/10.1016/S0140-6736(17)31145-5</mixed-citation><mixed-citation xml:lang="en">Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390(10099):1048-60. https://doi.org/10.1016/S0140-6736(17)31145-5</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019;394(10215):2155-64. https://doi.org/10.1016/S0140-6736(19)32514-0</mixed-citation><mixed-citation xml:lang="en">Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019;394(10215):2155-64. https://doi.org/10.1016/S0140-6736(19)32514-0</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Shah C, Jia X, Hobbs BP, et al. Outcomes with Partial Breast Irradiation vs. Whole Breast Irradiation: a Meta-Analysis. Ann Surg Oncol. 2021;28(9):4985-94. https://doi.org/10.1245/s10434-020-09447-w</mixed-citation><mixed-citation xml:lang="en">Shah C, Jia X, Hobbs BP, et al. Outcomes with Partial Breast Irradiation vs. Whole Breast Irradiation: a Meta-Analysis. Ann Surg Oncol. 2021;28(9):4985-94. https://doi.org/10.1245/s10434-020-09447-w</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Goldberg M, Bridhikitti J, Khan AJ, McGale P, Whelan TJ. A Meta-Analysis of Trials of Partial Breast Irradiation. Int J Radiat Oncol Biol Phys. 2023;115(1):60-72. https://doi.org/10.1016/j.ijrobp.2022.09.062</mixed-citation><mixed-citation xml:lang="en">Goldberg M, Bridhikitti J, Khan AJ, McGale P, Whelan TJ. A Meta-Analysis of Trials of Partial Breast Irradiation. Int J Radiat Oncol Biol Phys. 2023;115(1):60-72. https://doi.org/10.1016/j.ijrobp.2022.09.062</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet. 2019;394(10215):2165-72. https://doi.org/10.1016/S0140-6736(19)32515-2</mixed-citation><mixed-citation xml:lang="en">Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet. 2019;394(10215):2165-72. https://doi.org/10.1016/S0140-6736(19)32515-2</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Брянцева ЖВ, Акулова ИА, Яганова ТС и др. Сравнительный анализ дозиметрических планов при ускоренном частичном облучении больных раком молочной железы методом высокодозной брахитерапии и дистанционной лучевой терапии. Онкологический журнал: лучевая диагностика, лучевая терапия. 2024;7(3):34-40.</mixed-citation><mixed-citation xml:lang="en">Bryantseva ZhV, Akulova IA, Yaganova TS, et al. Dosimetric Comparison of Accelerated Partial Breast Irradiation Techniques: Multicatheter Interstitial Brachytherapy and Conformal External Beam Radiotherapy. Journal of Oncology: Diagnostic Radiology and Radiotherapy. 2024;7(3):34-40. (In Russ.). https://doi.org/10.37174/2587-7593-2024-7-3-34-40</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Polgár C, Van Limbergen E, Pötter R, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother On col. 2010;94(3):264-73. https://doi.org/10.1016/j.radonc.2010.01.014</mixed-citation><mixed-citation xml:lang="en">Polgár C, Van Limbergen E, Pötter R, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother On col. 2010;94(3):264-73. https://doi.org/10.1016/j.radonc.2010.01.014</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Брянцева Ж.В., Акулова И.А., Новиков С.Н., и др. Внутритканевая брахитерапия источниками высокой мощности дозы в лечении больных раком молочной железы. Онкологический журнал: лучевая диагностика, лучевая терапия. 2019;2(4):26-34.</mixed-citation><mixed-citation xml:lang="en">Bryantseva ZhV, Akulova IA, Novikov SN, et al. High Dose Rate Brachytherapy in Treatment of Breast Cancer Patients. Journal of Oncology: Diagnostic Radiology and Radiotherapy. 2019;2(4):26-34. (In Russ.). https://doi.org/10.37174/2587-7593-2019-2-4-26-34</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Polgár C, Ott OJ, Hildebrandt G, et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(2):259-68. https://doi.org/10.1016/S1470-2045(17)30011-6</mixed-citation><mixed-citation xml:lang="en">Polgár C, Ott OJ, Hildebrandt G, et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(2):259-68. https://doi.org/10.1016/S1470-2045(17)30011-6</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
